Re: Betting on hepatitis C: how financial speculation in drug development influences access to medicines
Access to medicines,particularly the recently introduced and expensive ones poses a huge challenge to public health systems with obligatory duties , and tends to produce a frustrating situations for clinicians where diagnosis is established and treatment remains elusive or compliance incomplete. The strategies employed by companies have discussed at length ; markets fluctuate and shareholders have to be kept satisfied. Limiting the buyback or setting standards for a fixed ratio between R&D and buyback could a possible solution.The non Europe/US situation can be different; low priced generics will invariably emerge..
Competing interests: No competing interests